An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Phio Pharmaceuticals Corp. announced positive data showing that the intratumoral injection of PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells. The compound is well tolerated, supporting its ongoing clinical trial as a neoadjuvant therapy for cSCC, melanoma, or Merkel cell carcinoma.
Phio Pharmaceuticals Corp. ha annunciato dati positivi che dimostrano come l'iniezione intratumorale di PH-762 inibisca significativamente la crescita dei tumori nei modelli murini e possa generare cellule T con memoria specifica. Il composto è ben tollerato, il che supporta il suo attuale sviluppo clinico come terapia neoadiuvante per il carcinoma a cellule squamose cutaneo, il melanoma o il carcinoma a cellule di Merkel.
Phio Pharmaceuticals Corp. ha anunciado datos positivos que muestran que la inyección intratumoral de PH-762 inhibe significativamente el crecimiento tumoral en modelos de tumores murinos y podría generar células T con memoria específica. El compuesto es bien tolerado, lo que respalda su ensayo clínico en curso como terapia neoadyuvante para el CSCC, melanoma o carcinoma de células de Merkel.
Phio Pharmaceuticals Corp.는 PH-762의 종양 내 주입이 생쥐 종양 모델에서 종양 성장을 현저히 억제하며 특정 기억 T 세포를 생성할 수 있다는 긍정적인 데이터를 발표했습니다. 이 화합물은 잘 견디며, 피부 편평세포암종, 흑색종 또는 메르켈 세포 암종에 대한 신접근 보조요법으로서 진행 중인 임상 시험을 지원합니다.
Phio Pharmaceuticals Corp. a annoncé des données positives montrant que l'injection intratumorale de PH-762 inhibe significativement la croissance tumorale dans les modèles de tumeurs murines et pourrait générer des cellules T à mémoire spécifique. Le composé est bien toléré, soutenant son essai clinique en cours comme thérapie néoadjuvante pour le cSCC, le mélanome ou le carcinome à cellules de Merkel.
Phio Pharmaceuticals Corp. hat positive Daten veröffentlicht, die zeigen, dass die intratumorale Injektion von PH-762 das Tumorwachstum in murinen Tumormodellen deutlich hemmt und möglicherweise spezifische Gedächtnis-T-Zellen erzeugt. Die Verbindung wird gut vertragen, was die laufende klinische Studie als neoadjuvante Therapie für cSCC, Melanom oder Merkelzellkarzinom unterstützt.
Positive
None.
Negative
None.
The recent report about Phio Pharmaceuticals' PH-762 and its ability to inhibit tumor growth in murine models represents an encouraging step forward in immuno-oncological therapies. The company's proprietary INTASYL siRNA gene silencing technology, which is at the heart of PH-762, is designed to augment the efficacy of immune cells in targeting and eradicating tumor cells. This technology could potentially revolutionize treatments for cancers such as cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma.
The fact that PH-762 is well-tolerated in murine models lays a robust foundation for its ongoing clinical trials. Tolerance is a critical factor in the advancement of any therapeutic candidate and the generation of memory-specific T cells could suggest a lasting immunological response, reducing the likelihood of cancer recurrence. Investors should note that while preclinical success in animal models doesn't guarantee clinical success in humans, it is a vital step in the drug development process. Phio Pharmaceuticals' progress could be a positive indicator for the company's valuation and future prospects, contingent on further clinical results.
As an oncologist, the progress reported with PH-762 is of significant interest. The approach of using intratumoral injection to elicit a systemic immune response is an advanced and very targeted cancer treatment strategy. This method has the potential to minimize systemic toxicity, a common issue with many cancer therapies. The ability to generate memory-specific T cells is particularly noteworthy—it suggests that the immune system could potentially 'remember' cancer cells and offer protection against future occurrences.
For investors interested in the biotechnology sector, Phio Pharmaceuticals' advancements with PH-762 highlight the company's innovative capabilities in a highly competitive oncology market. However, we must approach this optimism with caution, as the transition from murine to human models is complex and replete with challenges. Nevertheless, should PH-762 advance positively through the clinical trial phases, it could bode well for patient outcomes and, by extension, the company's market position and stock performance.
The announcement from Phio Pharmaceuticals regarding their PH-762 as a potential neoadjuvant therapy is a pivotal development that should capture the attention of investors. The use of the company's proprietary INTASYL technology in PH-762 could offer a competitive edge in the biotech market, particularly if subsequent clinical trials affirm the preclinical findings. The mention of neoadjuvant therapy indicates that PH-762 could be administered to shrink tumors before primary treatment, such as surgery, offering a potentially significant improvement in treatment paradigms.
From a financial perspective, if PH-762 continues to demonstrate efficacy and safety in humans, it could lead to an increase in Phio Pharmaceuticals' valuation. Investors often closely monitor biotech stocks for such breakthroughs, as they can be harbingers of substantial shifts in market dynamics. The company's focus on cSCC, melanoma and Merkel cell carcinoma - three areas with high unmet medical needs - could also mean sizeable market opportunities. Nevertheless, it is important to remain aware of the long timelines and high attrition rates typical of clinical trials, which can lead to volatility in biotech investing.
-Injection in murine tumors shows the compound is well tolerated
-Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
Preclinical studies demonstrate:
PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME)
Intratumoral injection of murine PH-762 (mPH-762) significantly inhibits tumor growth in murine tumor models and is well tolerated
mPH-762-mediated silencing of PH-762 within the TME may generate memory-specific T cells, promoting IFN-γ release in the TME
Studies in non-human primates demonstrate that PH-762 is well-tolerated and does not induce release of cytokines associated with cytokine release syndrome (CRS)
These finding support the ongoing clinical trial of PH-762’s safety and efficacy as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma
The data, authored by Melissa Maxwell, Linda Mahoney, and Dr. Mary Spellman, will be presented at the American Society of Gene and Cell Therapy (ASGCT) on May 8th in Baltimore, Maryland.
Presentation Details are as follows:
Title:
INTASYL PH-762: PD-1 Intratumoral Immunotherapy
Abstract Number:
774
Session Title:
Cancer-Immunotherapy and Cancer Vaccines
Authors:
Melissa Maxwell, Linda Mahoney, Mary Spellman, M.D.
Date and Time:
May 8, 2024 12:00 PM
Location:
Exhibit Hall
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
For additional information, visit the Company’s website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
phio pharmaceuticals corp., a biotechnology company, develops immuno-oncology therapeutics in the united states. it offers intasyl therapeutic platform focuses on silencing tumor-induced suppression of the immune system. the company develops ph-762 which targets the checkpoint protein pd-1 on immune cells for used in adoptive cell transfer (act); ph-804 that targets the suppressive immune receptor tigit, which is a checkpoint protein present on t cells and natural killer cells for used in act; and ph-790 which targets pd-l1 protein that keeps immune cells from attacking nonharmful cells in the body. it has collaborations with the gustave roussy and medigene ag, as well as with helmholtz zentrum mã¼nchen. the company was formerly known as rxi pharmaceuticals corporation and changed its name to phio pharmaceuticals corp. in november 2018. phio pharmaceuticals corp. was incorporated in 2011 and is headquartered in marlborough, massachusetts.
